Largest Companies World Wide
OrganiGram, a Toronto Stock Exchange listed company and a licensed producer of medical marijuana in Canada, is ranked as the ninth largest marijuana company with a market capitalization of $664.26 million.
The company’s facility is located in Moncton, New Brunswick.
OrganiGram said in early June that it received an expanded cultivation license from Health Canada related to its previously announced Phase 3 expansion.
Once the remaining Phase 3 rooms are online, the company will have a target production capacity of 36,000 kg per year of dried flower equivalent.
Canada-based CannTrust stood in eighth position among the world’s biggest marijuana companies with a market capitalization of $846.54 million. The company’s shares recently commenced trading on the Toronto stock exchange.
CannTrust currently operates a 60,000 square foot state-of-the-art hydroponic facility in Vaughan, Ontario, as well as the recently completed 250,000 square foot Phase 1 redevelopment of its 450,000 square foot Niagara Greenhouse Facility.
The Phase 2 expansion, currently underway, is anticipated to be completed and in cultivation towards the middle of 2018.
It has an exclusive global partnership with Apotex, a Canada-based pharmaceutical company.
The Hydropothecary Corp
The Hydropothecary Corp. stood in seventh position among the world’s largest cannabis companies with a market capitalization of $943.54 million.
It is the only licensed producer headquartered in Quebec, and also counts itself as one of Canada’s lowest-cost producers.
The company is currently expanding its facilities to 1.3 million square feet and its production capacity to 108,000 kilogram of dried cannabis per year.
Hydropothecary will supply the recreational cannabis markets in Canada and elsewhere under its newly launched HEXO brand that will focus on recreational marijuana use, and will also continue to serve medical cannabis clients under its original Hydropothecary brand.
Cronos Group, a Canadian licensed producer and distributor of medical cannabis that also has a footprint in Germany, Israel, and Australia, stood in sixth position among the world’s biggest marijuana companies with a stock market capitalization of $1.24 billion.
The company recently became the first pure-play cannabis company to trade on a major U.S. stock exchange, the Nasdaq.
Cronos operates two wholly-owned Canadian licensed producers under Health Canada's Access to Cannabis for Medical Purposes Regulations: Peace Naturals Project Inc. and Original BC Ltd.
In March, Cronos and MM Enterprises USA said they formed a cross-border joint venture to cater to Canadian consumers ahead of Canada’s plans to legalize adult use of cannabis this year.
With an estimated market value of $1.4 billion, it was the first company to invest in Portugal. Canadian cannabis producer Tilray executives first visited Portugal in 2015. After conducting extensive due diligence, consultation with stakeholders, and a country-wide property search, Tilray reached a Memorandum of Understanding with the Government of Portugal in October 2016. Tilray Portugal Unipessoal Lda. Was incorporated in March 2017. The company purchased property in Cantanhede in July 2017.
Tilray says it will invest about $29.5 million in a medical cannabis operation in Portugal after winning federal licenses there to import cannabis seeds and clones and cultivate them.
It says it plans to establish a campus at Cantanhede, about 220 kilometers north of Lisbon, that will grow, process and package medical cannabis products for distribution across the European Union.
CEO Brendan Kennedy says the licenses are the culmination of a two-year search for a location from which to serve demand for cannabis in Europe, adding Tilray estimates the market could grow to 10 million patients and generate as much as 40 billion euros per year in revenue.
“We’re seeing massive demand from Germany so we needed to build a large facility to meet that demand and we needed to get it up and running very quickly,” he said.
“And Portugal seemed like the ideal location to grow plants.”
Kennedy said Tilray is the first company — foreign or domestic — to win a licence to grow cannabis containing the active ingredient THC in Portugal.
Tilray says its first phase will feature outdoor growing fields plus 108,000 square feet of greenhouses, 1,600 square feet of processing facilities, and a laboratory and genetics bank, located in and around the BIOCANT Research Park in Cantanhede.
Construction is to start this month and be completed by next spring, creating 100 local jobs and growing 100000 plants.
The Portugal operation would be its first outside of Canada.
Aphria, one of Canada’s lowest cost producers of marijuana, is ranked fifth among the biggest marijuana companies with a market capitalization of $2.44 billion.
The company is based in Leamington, Ontario, the greenhouse capital of Canada.
In early June, Aphria said it will build a state-of the art Extraction Centre of Excellence, along with other investment plans.
The company noted that all the operational changes it announced will result in an increased capacity of 30,000 kilograms, bringing Aphria’s total annualized capacity to 255,000 kilograms.
Canada-based MedReleaf Corp. is ranked as the world’s fourth-largest marijuana company with a market capitalization of $2.64 billion.
The company has two ICH-GMP and ISO 9001 certified facilities in Ontario, with a third facility currently in development. In May, MedReleaf agreed to be acquired by larger Canadian peer Aurora Cannabis for C$3.2 billion.
MedReleaf recently closed its previously-announced agreement to acquire 1 million square feet of existing greenhouse infrastructure on a 69 acre property in Exeter, Ontario and 95 acres of adjacent land.
The Exeter facility will have annual production capacity of up to 105,000 kilograms, increasing MedReleaf's fully funded annual production capacity to 140,000 kilograms.
Cambridge, UK-based GW Pharmaceuticals is a biopharmaceutical company that is engaged in developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It is the third-largest marijuana company with a market capitalization of $4.28 billion.
The company’s lead product is Epidiolex, a cannabidoil-based drug that is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Epidiolex has received orphan drug and fast-track designation from the U.S. Food and Drug Administration.
Aurora Cannabis, also based in Canada, is the world’s second-largest marijuana company with a market capitalization of $5.12 billion.
It also operates as a pharmaceutical wholesaler and narcotics dealer of medical marijuana in Germany and the European Union.
In May, Aurora Cannabis agreed to acquire smaller rival MedReleaf Corp. for C$3.2 billion, marking its second acquisition this year.
In January, the company and CanniMed Therapeutics Inc. ended a protracted takeover battle with a friendly $1.1 billion merger between the two marijuana giants.
Aurora Cannabis is poised to be the world's largest marijuana company after completion of these acquisitions.
Canopy Growth Corp
Canada-based Canopy Growth is the largest marijuana company in the world with a market capitalization of $6.03 billion.
Formerly known as Tweed Marijuana, the company changed its name to Canopy Growth in September 2015.
Canopy Growth operates ten cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The company has operations in eight countries across five continents.